Abstract
There has been a lot of debate about the use of the Adenosine Deaminase (ADA) for tuberculosis (TB) diagnosis. In the present study, to overcome this debate, we have planned a large scale study in all forms of TB to access the performance of ADA for diagnosis of TB. we have also studied the performance of the ADA in the Tb prognosis. ADA activity was evaluated using Guisti and Galanti method. The sensitivity of the ADA test is impressive in all forms of TB clinical samples analysed for the study (PTB [82%], TBM [85%] TBAR [85%]), and (ATB) [84%]. However, the specificity was variable in pulmonary TB, but satisfactory in extrapulmonary TB (EPTB) cases (i.e TBM [89%], (ATB) [88%], TBAR [88%]). In the follow-up samples, ADA value declined drastically after the anti TB medication (ATT). Our study, which consists of a large number of samples, suggests that the ADA has very limited value in the diagnosis of PTB, and hence it is not recommended for PTB diagnosis. We recommend, ADA test is quite useful for EPTB diagnosis along with other clinical correlations and in absence of other advanced diagnostic tests. However, on the other ADA can be used as a prognostic test for all forms of TB.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by CIIMS as an In house project.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The present observational study (prospective and retrospective) study was approved by the Institutional Ethics Committee, of Central India Institute of Medical Sciences (CIIMS), Nagpur.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All the data was generated during the course of the study.
